Segments - Artificial Organs Market by Organ Type (Artificial Kidney, Artificial Heart,Artificial Lungs, Cochlear Implants,Artificial Pancreas, and Others), Material Type (Biomaterials, Plastic, Steel, and Silicone),Technology (Electronic and Mechanical),End-user (Laboratories & Diagnostic, Hospitals, Ambulatory Surgical Centers, and Research &Academic Institute),and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size,Trends, andForecast 2023 – 2031
The artificial organs market size was valued at USD 23.5 Bn in 2022 and is likely to reach USD 46 Bn by 2031, expanding at a CAGR of 7.85% during 2023–2031. The market is likely to be driven by rising chronic diseases, the rapid growth of geriatric population, and the increasing acceptance of organ transplants.
Artificial organs are human-developed organ devices or tissues that are integrated or implanted into the human body. Healthcare professionals replace faulty or missing natural organs with artificial organs to elevate specific body functions and help patients to resume their normal life. Artificial organs are constructed on biophysical, mechanical, and electrical characteristics to support human organs.
Artificial organs are typically created using biomedical engineering and regenerative medicine techniques. They are made from biocompatible materials and incorporate advanced technologies such as sensors, actuators, and electronic components to mimic the functions of natural organs. The commonly replaced or augmented organs include the heart, kidneys, liver, lungs, pancreas, and limbs.
The primary use of artificial organs is to replace damaged or failed organs in the human body. For example, artificial hearts, also known as ventricular assist devices (VADs), can be used for transplantation or as a long-term solution for patients with severe heart failure. Artificial organs provide an alternative solution, reducing the dependency on donor organs and eliminating the need for organ transplantation completely in certain cases.
The COVID-19 pandemic affected the global artificial organs market. The healthcare systems worldwide focused on managing COVID-19 patients and many elective surgeries, including organ transplantations were postponed, further reducing the product expansions. Carrying out implant procedures during the pandemic situation was a risk factor, as doctors and patients required an operation theatre that is free of viral infections. These criteria hampered the market.
Post-pandemic, the importance of maintaining overall organ health grew significantly among individuals with pre-existing organ conditions. This increased awareness of research and development in artificial organs to address the needs of patients with organ failure or damage.
Rising geriatric population across the globe is one of the factors propelling the market. Aging increases the risk of developing chronic diseases such as cardiovascular disorders, kidney failure, and liver disease. These conditions often require organ and tissue transplantation or the use of artificial organs to maintain normal body functions.
According to the Health Resources and Services Administration (HRSA), the number of organ transplant procedures conducted on individuals aged 65 and above in the United States reached more than 42,800 in 2022. This data underscores the growing demand for artificial devices driven by an elevated life expectancy and an increased need for organ donors.
Increasing prevalence of organ failure is another factor expected todrive the global artificial organ market. Organ failures occur due to cardiovascular disease, severe infections, and trauma-raising organ transplant surgeries.
The rising prevalence of severe sepsis driving the demand for implantation of artificial organs. Sepsis is a condition where harmful microorganisms are present in the blood or tissue which leads to organ failure. If it is not addressed on time, the disease can even lead to the death of an individual.
Almost 1 in 5 cases of sepsis cause death around the world. About 47 to 50 million sepsis cases occur every year and at least 11 million deaths are associated with this disease. Such a prevalence of sepsis is expected to fuel the need for artificial organs in the coming years.
Lack of skilled professionals and transplant-associated side effects hampers the market.The main concern related to transplant is the possibility of the presence of the disease in the base tissue used to create the organ. Foreign body tissue is sometimes used to reconstruct or regenerate an organ. There is a possibility of such tissues being already infected with another disease. In such a scenario, there is a high risk of organ failure, and the body might need time to adjust to the new organ.
Advances in 3D bioprinting create lucrative opportunities for the market.The field of 3D bioprinting is crucial in organ transplantation as it is used for developing artificial organs. This technology reduces the risk of organ rejection while transplantation. 3D bioprinting allows for the customization of artificial organs according to the specific needs and anatomical variations of individual patients.
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Artificial Organs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2022 |
Historic Data |
2016–2021 |
Forecast Period |
2023–2031 |
Segmentation |
Organ Type (Artificial Kidney, Artificial Heart, Artificial Lungs, Cochlear Implants, Artificial Pancreas, and Others), Material Type (Biomaterials, Plastic, Steel, and Silicone), Technology (Electronic and Mechanical), andEnd-user (Laboratories & Diagnostic, Hospitals, Ambulatory Surgical Centers, and Research & Academic Institute) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, MarketTrends, and Revenue Forecast |
Key Players Covered in the Report |
Zimmer Biomet; Abbott; SynCardia Systems, LLC.; Medtronic,Vanderbilt University Medical Center; ABIOMED; Berlin Heart; Boston Scientific Corporation, Edwards Lifesciences Corporation; Ekso Bionics; iWalkFree; Inc., and Jarvik Heart, Inc. |
On the basis of organ type, the global artificial organs market is divided into artificial kidney, artificial heart, artificial lungs, cochlear implants, artificial pancreas, and others.The artificial kidney segment is expected to expand at a substantial growth rate during the projection period due to rising incidences of kidney diseases and the low availability of kidney donors.
Kidney diseases, such as chronic kidney disease (CKD) and end-stage renal disease (ESRD), are becoming more prevalent worldwide. Factors such as aging populations, unhealthy lifestyles, and the increased prevalence of conditions including diabetes and hypertension contribute to the rising incidence of kidney diseases.
According to data published bythe National Institutes of Health in March 2022, there is a rise in cases of chronic kidney disease around the world. It states that CKD is a progressive health condition, that infects 10% of the general population worldwide. This implies that there are more than 800 million individuals suffering from this disease and also it is more prevalent among the geriatric population.
The artificial heart segment is expected to expand at a significant growth rate in the coming yearsdue to the increasing incidence of heart failure. Cardiovascular diseases, including heart failure,are a major contributor to illness and death.Artificial hearts have the potential to save lives by providing immediate support to individuals with end-stage heart failure.They offer crucial solutions for individuals in need of a heart transplant or those who are ineligible for transplantation due to factors such as age or medical conditions.
Artificial hearts, including ventricular assist devices (VADs) and total artificial hearts, are crucial in providing mechanical support for individuals with severe heart failure. These devices help to maintain blood circulation and improve the quality of a patient’slife.
On the basis of material type, the global market is segregated into biomaterials, plastic, steel, and silicone.The biomaterials segment is projected to register a considerable CAGR during the forecast period due toits ability to support tissue engineering and biocompatibility.
Biomaterials play a pivotal role in the advancement of artificial organs by furnishing a scaff old or matrix that facilitates cell growth and tissue regeneration. Various artificial organ applications heavily rely on biocompatible materials, including biodegradable polymers, hydrogels, and naturally occurring substances such ascollagen and alginate.
Biomaterials used in artificial organs exhibit high biocompatibility, signifying their capacity to be well-tolerated by the human body without causing adverse reactions. This compatibility plays a critical role in the successful combination and functionality of artificial organs within the recipient's body.
The plastic segment is anticipated to hold a significant share of the market, due toits durability and mechanical strength. Plastic materials are known for their durability and mechanical strength.Plastic materials, such as polymethyl methacrylate (PMMA) and polyurethane, find applications in certain artificial organs. For example, plastic materials are used in the construction of artificial joints, including knee and hip replacements.
the global artificial organs market is segmented into electronics and mechanical.The mechanical segment is expected to register a robust growth rate during the forecast period due to the increasing prevalence of organ failure and cost-effectiveness.
The increasing incidence of organ failures such as heart failure or lung disease, is posing challenges for the healthcare system around the world. Mechanical technology provides alternatives to natural organs by developing artificial organs or assistive devices that can take completely or partially replace the function of failed organs.
Mechanical technology provides cost-effective substitutes for transplantation that do not require tissue-matching organs from donors. These mechanical devices are manufactured at a lower cost compared to the traditional process of organ transplantation.
the global artificial organ market is segregated into laboratories & diagnostic, hospitals, ambulatory surgical centers, and research & academic institutes. The hospitals segment is expected to hold a significant market share during the forecast period, due to the higher number of organ transplants performed in hospital settings.
Hospitals have specialized infrastructure and facilities that are required for organ transplantation procedures. They have dedicated operation theaters equipped with advanced surgical instruments, monitoring systems, and anesthesia equipment. Also, they have intensive care units (ICUs) and transplant wards that provide specialized care for patients before, during, and after transplantations.
The research and academic institute segment is projected to expand at a considerable growth rate during the projection period due to the development and advancement of artificial organ technologies.Research and academic institutes have the resources, expertise, and infrastructure to conductin-depth research and development in artificial organs. They have established relationships with government bodies, supports financially which enables institutions to invest in types of equipment and laboratory facilities.
In terms of region, the global artificial organs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.North America is expected to dominate the market during the projection period due to the rising numbers of transplant surgeries and the high incidence of organ failures among the population.
The presence of well-established healthcare facilities in the field of artificial organs and the local presence of prominent biotechnology and medical device companies are supporting the market growth in the region. Major companies such as Zimmer Biomet, Arthrex, Inc., Medtronic, Novartis AG, and Strykerare present in the region.
For instance, In March 2022, Zimmer Biomet Holdings Inc.introduced WalkAI, an advanced AI technology designed to identify patients who are likely to have a reduced gait speed outcome within ninety days following hip or knee surgery. WalkAI is an integral part of ZBEdge, a comprehensive suite of interconnected intelligent robotic technologies that leverage data-driven insights to enhance patient outcomes.
The market in Asia Pacific is projected to grow rapidly during the forecast period, owing to the presence of large populations with a high incidence of chronic diseases. Rising government initiatives and healthcare organizations have been focusing on expanding healthcare access and improving medical services. Asia Pacific witnessed significant advancements in medical research and technology. Emerging economies such as India, China, and Japan have been the leaders of innovation in the field of artificial organs.
The global artificial organs market has been segmented on the basis of
Key players competing in the artificial organs market are Zimmer Biomet; Abbott; SynCardia Systems, LLC.; Medtronic,Vander bilt University Medical Center; ABIOMED; Berlin Heart; Boston Scientific Corporation, Edwards Lifesciences Corporation; Ekso Bionics; WalkFree; Inc., and Jarvik Heart, Inc.
The major players in the artificial organ market are developing various strategies such as partnerships, mergers, collaboration,innovations, and new product launches to expand their offerings, technological advancements, and consumer base. These companies are recognized for their contributions to advancements in healthcare and have played a significant role in the development and commercialization of innovative technologies for the improvement of patient outcomes. For instance,
In February 2022, Vanderbilt University Medical Center, the Department of Defense Congressionally Directed Medical Research Program (CDMRP), Vanderbilt University Medical Center, Carnegie Mellon University, and Cornell University have been awarded a four-year grant totaling USD 87 million. The funding aims to support the development of an artificial lung platform designed to address the needs of patients with untreatable lung diseases who are unable to wait for a lung transplant.